On September 7, 2022 Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, reported that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 (Press release, Precision Biosciences, SEP 7, 2022, View Source [SID1234619161]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the in-person fireside chat are as follows:
Date: Tuesday, September 13, 2022
Time: 4:30 PM ET
Location: Lotte New York Palace Hotel

The fireside chat will be available via a recorded webcast accessible on Precision’s website in the Investors section under Events & Presentations on September 14, 2022: View Source An archived replay will be available for approximately 30 days following the event.